Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study

Cruz, Luis J.; Rosalia, Rodney Alexander; Kleinovink, Jan Willem; Rueda, Félix; Löwik, Clemens W.G.M.; Ossendorp, Ferry

doi:10.1016/j.jconrel.2014.07.040

Cited by 197 publications

(139 citation statements)

References 35 publications

Supporting

Mentioning

136

Contrasting

Order By: Relevance

“…Incorrect targeting can result in immune stimulation. For example, antigen-loaded NPs that are designed to target CD40, DEC205, or CD11c induce robust production of IL-12 and type 2 interferon as well as CD8+ T cell proliferation [85], whereas particles that target MARCO+ macrophages in the liver and spleen induce tolerance [6]. This highlights the fact that APC populations are not created equal, with some populations better equipped for tolerance induction and others equipped for immune induction.…”

Section: Np Development For Tolerancementioning

confidence: 99%

Harnessing Nanoparticles for Immune Modulation

Getts¹,

Shea²,

Miller³

et al. 2016

Trends in Immunology

View full text Add to dashboard Cite

Recent approaches using nanoparticles engineered for immune regulation have yielded promising results in preclinical models of disease. The number of nanoparticle therapies is growing, fueled by innovations in nanotechnology and advances in understanding of the underlying pathogenesis of immune-mediated diseases. In particular, recent mechanistic insight into the ways in which nanoparticles interact with the mononuclear phagocyte system and impact its function during homeostasis and inflammation have highlighted the potential of nanoparticle-based therapies for controlling severe inflammation while concurrently restoring peripheral immune tolerance in autoimmune disease. Here we review recent advances in nanoparticle-based approaches aimed at immune-modulation, and discuss these in the context of concepts in polymeric nanoparticle development, including particle modification, delivery and the factors associated with successful clinical deployment.

show abstract

Section: Np Development For Tolerancementioning

confidence: 99%

Harnessing Nanoparticles for Immune Modulation

Getts¹,

Shea²,

Miller³

et al. 2016

Trends in Immunology

View full text Add to dashboard Cite

show abstract

“…C57BL/6 mice (five per group) were immunized with DCs treated with PLGA-NPs (2×10 6 ) pulsed with or without OVA peptide (1 μg/mL), and splenocytes were harvested and analyzed by flow cytometry 7 days after the last immunization. Mice vaccinated with PLGA (OVA + poly I:C)-NP-treated DCs pulsed with OVA peptides generated significantly higher numbers of activated CD8 + T cells as measured by IFN-γ secretion ( Figure 6A).…”

Section: In Vivo Antigen-specific Cd8mentioning

confidence: 99%

“…After internalizing antigen and adjuvant into DCs, DCs can exhibit antigen cross-presentation to cytotoxic T cells through extracellular major histocompatibility complex (MHC)-I molecules. 6 Therefore, effective maturation of DCs is the key first step in DC-based cancer immunotherapy. Because antigen or adjuvant show limited penetration into DCs, efficient delivery systems are highly suitable for both antigen and adjuvant delivery into DCs.…”

Section: Introductionmentioning

confidence: 99%

Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy

Han¹,

Byeon²,

Kang³

et al. 2016

IJN

View full text Add to dashboard Cite

“…OVA), Pam3CSK4 and Poly(I:C) and α-CD40-mAb showed highly efficient delivery to DC in the in vivo model when injected in mice, stimulated significantly boosted CD8 + T cell responses, and prolonged the survival rate in vaccinated mice compared to non-treated and nontargeted nanoparticle control [22] . A comparative study of targeting various DC cell-surface molecules indicated that CD40, DEC-205 or CD11c targeted nanoparticle showed similar capability to induce CD8 + T cell immune response [23] .…”

Section: Dendritic Cellsmentioning

confidence: 99%

Role of targeting nanoparticles for cancer immunotherapy and imaging

Wen¹,

Umeano

2017

Trends Immunother

View full text Add to dashboard Cite

Cancer immunotherapy involves the delivery of immunogenic compounds and/or the priming, or induction, of the body's natural immune system to target cancer. The use of cancer immunotherapy has led to various means of cancer prevention and treatment that have produced prolonged life expectancy and stabilized disease. Nanoparticles are promising vehicles or adjuvants for effective delivery of therapeutics, antigens, stimulatory effectors, or antibodies for therapeutic invention. Targeting nanoparticles are especially useful due to their capability of accumulating in specific sites of interest like tumors and, thereby, decreasing risks of damage to normal tissue. Targeting can be achieved by incorporation of cell-surface related binding molecules or antibodies. This review explores the role of targeting nanoparticles as delivery or adjuvant systems to modulate immune response, and as imaging tracking systems for cancer immunotherapy. Keywords: nanoparticles; cancer immunotherapy; imaging; targeting ARTICLE INFO

show abstract

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study

Cited by 197 publications

References 35 publications

Harnessing Nanoparticles for Immune Modulation

Harnessing Nanoparticles for Immune Modulation

Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy

Role of targeting nanoparticles for cancer immunotherapy and imaging

Contact Info

Product

Resources

About